Urinary cystatin B differentiates progressive versus stable IRIS Stage 1 chronic kidney disease in dogs.

Bibliographic Details
Title: Urinary cystatin B differentiates progressive versus stable IRIS Stage 1 chronic kidney disease in dogs.
Authors: Segev, Gilad, Vaden, Shelly, Ross, Sheri, Dufayet, Cedric, Cohn, Leah A., Farace, Giosi, Szlosek, Donald, Ouyang, Zenhwa, Peterson, Sarah, Beall, Melissa, Yerramilli, Murthy, Polzin, David, Cowgill, Larry D.
Source: Journal of Veterinary Internal Medicine; Nov/Dec2023, Vol. 37 Issue 6, p2251-2260, 10p
Subject Terms: CHRONIC kidney failure, DOG diseases
Abstract: Background: Early identification of dogs with progressive vs stable chronic kidney disease (CKD) might afford opportunity for interventions that would slow progression. However, currently no surrogate biomarker reliably predicts CKD progression. Hypothesis/Objectives: Urinary cystatin B (uCysB), a novel kidney injury biomarker, predicts progressive disease in International Renal Interest Society (IRIS) CKD Stage 1. Animals: Seventy‐two dogs, including 20 dogs from 4 university centers with IRIS CKD Stage 1, with IDEXX symmetric dimethylarginine (SDMA) concentration up to 17 μg/dL and no systemic comorbidities, and 52 clinically healthy staff‐owned dogs from a fifth university center. Methods: A multicenter prospective longitudinal study was conducted between 2016 and 2021 to assess uCysB concentration in IRIS CKD Stage 1 and control dogs. Dogs were followed to a maximum of 3 years (control) or 25 months (CKD). Stage 1 IRIS CKD was classified as stable or progressive using the slope of 1/SDMA, calculated from 3 timepoints during the initial 90‐day period. Dogs with slope above or below −0.0007 week × dL/μg were classified as stable or progressive, respectively. Mixed effects modeling was used to assess the association between uCysB and progression rate. Results: Estimates of first visit uCysB results predictive of active ongoing kidney injury based on the mixed effects models were 17 ng/mL for control, 24 ng/mL for stable CKD, and 212 ng/mL for progressive CKD (P <.001). Conclusions and Clinical Importance: Urinary cystatin B differentiated stable vs progressive IRIS CKD Stage 1. Identification of dogs with progressive CKD may provide an opportunity for clinicians to intervene early and slow progression rate. [ABSTRACT FROM AUTHOR]
Copyright of Journal of Veterinary Internal Medicine is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Complementary Index
More Details
ISSN:08916640
DOI:10.1111/jvim.16887
Published in:Journal of Veterinary Internal Medicine
Language:English